Extrapulmonary Neuroendocrine Carcinoma

Extrapulmonary Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

315 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 104
Recruiting: 46
Ph III recruiting: 1
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (50)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07472322	ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1	not yet recruiting	Phase 1 / Phase 2	31	University of Wisconsin, MadisonOTHER	1	Sep 29, 2026	clinicaltrials
NCT07576725	Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial	not yet recruiting	Phase 2	50	Fred Hutchinson Cancer CenterOTHER	1	Sep 17, 2026	clinicaltrials